0.00Open0.02Pre Close0 Volume34 Open Interest35.00Strike Price0.00Turnover535.18%IV537.89%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier7DDays to Expiry0.02Extrinsic Value100Contract SizeAmericanOptions Type0.0171Delta0.0105Gamma274.50Leverage Ratio-0.0099Theta0.0000Rho4.70Eff Leverage0.0003Vega
4D Molecular Therapeutics Stock Discussion
4DMT Announces Positive Interim Data from 4D-150 SPECTRA Clinical Trial in DME and Alignment with FDA on Registrational Path
3 minutes ago, 5:00 AM PST
Via GlobeNewswire
FDMT
Share
• Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level
• 3E10 vg/eye demonstrated strong signals of clinical activity with sustained gain of BCVA of +8.4 letters and reduction of ...
🌈 静待股价回落,长线标的,观察仓开仓目标价14.85
⭕ Regulation FD Disclosure.
On July 23, 2024, 4D Molecular Therapeutics, Inc. (the “Company”) reported that interim longest available follow up data from the Phase 1 Dose Expansion cohort, Phase 2 Dose Expansion cohort, and Phase 2 Population Extension cohort from its Phase 1/2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration are expected to be presented at a medical conference in Septemb...
» Holdings in Top 20: 70.21%
» Qtr over Qtr Change**: +21.81%
Top Holdings:
$Ascendis Pharma A/S (ASND.US)$
$Vaxcyte (PCVX.US)$
$Legend Biotech (LEGN.US)$
$Janux Therapeutics (JANX.US)$
$Aerovate (AVTE.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Evolent Health (EVH.US)$
$NewAmsterdam Pharma (NAMS.US)$
$RxSight (RXST.US)$
$TYRA BIOSCIENCES, INC. (TYRA.US)$
$Edgewise Therapeutics (EWTX.US)$
$4D Molecular Therapeutics (FDMT.US)$
$Biogen (BIIB.US)$
$PepGen (PEPG.US)$